tirzepatide law firm in louisiana glp-1 pancreatitis Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes Louisiana Civil Law Treatise V.2
Description
The FDA approved Zepbound based on the SURMOUNT clinical trial program , which enrolled over 5,000 participants across multiple phase 3 studies
Clinical trials showed that approximately 4-6% of participants discontinued Zepbound specifically due to gastrointestinal adverse effects
Most researchers are better served by completing the standard 4-week initiation period on 2.5mg and then moving to 5mg rather than splitting the starting dose
This is not failure
At just 50 units (half a syringe), the injection volume is small and comfortable
